Nanoparticles

Nanoparticles

Lipid nanoparticles (LNPs) have emerged as the leading platform for mRNA delivery, protecting RNA from degradation, facilitating cellular uptake, and supporting scalable manufacturing across modern RNA therapeutics.

Because LNP performance is highly dependent on formulation and process, development requires careful optimization of particle design, encapsulation, and characterization. Artis is expanding its mRNA and LNP capabilities to support formulation development, process optimization, and clinical translation.

Want to learn more?

If you are interested in learning more about our mRNA and LNP capabilities, please contact us to discuss your program.

Quality and Compliance

cGMP facilities and operations are designed to meet applicable US FDA regulations (including 21 CFR Parts 11, 210, 211, 610, and 1271) and relevant ICH quality guidelines.